Revance Therapeutics (RVNC)

Revance Therapeutics (RVNC) Financial Statements


Revance Therapeutics Financial Overview

Revance Therapeutics's market cap is currently ―. The company's EPS TTM is $-3.789; its P/E ratio is -1.30; Revance Therapeutics is scheduled to report earnings on May 7, 2024, and the estimated EPS forecast is $-0.48. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue$ 69.80M$ 56.78M$ 58.13M$ 49.33M$ 49.92M
Gross Profit$ 52.33M$ 37.36M$ 36.83M$ 49.33M$ 57.25M
EBIT-$ -131.95M$ -59.54M$ -55.30M$ -143.71M
EBITDA-$ -131.16M$ -56.94M$ -53.29M$ -127.46M
Net Income Common Stockholders$ -55.70M$ -141.18M$ -67.32M$ -59.79M$ -145.95M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 253.91M$ 300.25M$ 320.00M$ 274.22M$ 340.71M
Total Assets$ 478.45M$ 532.49M$ 597.53M$ 547.80M$ 581.90M
Total Debt$ 478.43M$ 487.90M$ 432.39M$ 435.72M$ 418.47M
Net Debt$ 224.52M$ 187.65M$ 112.39M$ 161.49M$ 77.76M
Total Liabilities$ 630.06M$ 638.69M$ 570.75M$ 574.47M$ 569.30M
Stockholders Equity$ -151.60M$ -106.20M$ 26.79M$ -26.67M$ 12.60M
Cash Flow-
Free Cash Flow-$ -55.47M$ -53.10M$ -70.38M$ -31.47M
Operating Cash Flow$ -42.73M$ -50.96M$ -53.36M$ -69.51M$ -30.18M
Investing Cash Flow$ 2.37M$ 51.59M$ -39.53M$ 95.32M$ 40.96M
Financing Cash Flow$ -1.63M$ 37.46M$ 97.47M$ 3.27M$ -6.17M
Currency in USD

Revance Therapeutics Earnings and Revenue History

Revance Therapeutics Debt to Assets

Revance Therapeutics Cash Flow

Revance Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis